Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phosphatidylserine-Omega3 in Children with ADHD
NCT00382616Phase 2Completed
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of phosphatidylserine + omega-3 in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoints: Test of Variables of Attention at 3 months and Blood lipids profile at 3 months. Started Jul 2004; status: completed.
02
Drugs
phosphatidylserine + omega-3
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00382616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00382616.